Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2004-05-17
2008-09-30
Prouty, Rebecca (Department: 1652)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S094500, C435S232000
Reexamination Certificate
active
07429375
ABSTRACT:
The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
REFERENCES:
patent: 7008783 (2006-03-01), Sato et al.
patent: 2005/0233419 (2005-10-01), Pojasek et al.
patent: 2006/0078959 (2006-04-01), Prabhakar et al.
patent: 94/25567 (1994-11-01), None
Yamagata, T., et al., J. Biol. Chem. 243:1523, 1968, (Abstract only).
Sato et al., Agric. Biol. Chem. 50(4):1057-1059, 1986.
Caggiano Anthony O.
D'Souza Rohini
Gruskin Elliott A.
Roy Gargi
Acorda Therapeutics, Inc.
Pepper Hamilton LLP
Prouty Rebecca
LandOfFree
Proteoglycan degrading mutants for the treatment of CNS does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteoglycan degrading mutants for the treatment of CNS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteoglycan degrading mutants for the treatment of CNS will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3972870